Clinical Trials Logo

Malignant Melanoma clinical trials

View clinical trials related to Malignant Melanoma.

Filter by:

NCT ID: NCT00145041 Completed - Malignant Melanoma Clinical Trials

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Start date: February 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics). This study will also assess the safety of VSLI and to see if VSLI will slow the growth or shrink tumors in patients with metastatic melanoma that has resulted in liver impairment, and who have relapsed after previous therapies.

NCT ID: NCT00142454 Completed - Malignant Melanoma Clinical Trials

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Start date: August 24, 2005
Phase: Phase 1
Study type: Interventional

This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity of treatment.

NCT ID: NCT00135408 Completed - Malignant Melanoma Clinical Trials

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.

NCT ID: NCT00116363 Recruiting - Neoplasm Metastasis Clinical Trials

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

NCT ID: NCT00111696 Completed - Malignant Melanoma Clinical Trials

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Start date: May 2005
Phase: Phase 1
Study type: Interventional

To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.

NCT ID: NCT00108875 Recruiting - Pancreatic Cancer Clinical Trials

Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer

Start date: April 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety, the immunological response and the clinical outcome of a vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and cervical carcinoma.

NCT ID: NCT00104884 Terminated - Melanoma Clinical Trials

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Start date: October 4, 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable stage III or stage IV malignant melanoma.

NCT ID: NCT00087776 Completed - Malignant Melanoma Clinical Trials

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

Start date: October 2002
Phase: N/A
Study type: Interventional

The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.

NCT ID: NCT00087477 Terminated - Malignant Melanoma Clinical Trials

A Pilot Study of Pivanex in Patients With Malignant Melanoma

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.

NCT ID: NCT00086489 Completed - Malignant Melanoma Clinical Trials

CP-675,206 In Patients With Advanced Melanoma

Start date: August 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma